Lund-based MedVasc has raised €2.2 million through subscriptions exclusively from existing shareholders, as well as completing production and testing activities for their anesthesia catheter Solutio, advancing toward FDA clearance.
This follows May 2025’s €917k financing round, as covered by EU-Startups.
”The strong participation from current owners demonstrates continued confidence in MedVasc’s strategy, execution capability, and long-term value creation. The board and management view this support as a clear validation of the company’s direction and its ongoing development efforts,” says Cathrin Johansson, CEO of MedVasc.
Analysis of 2025–2026 shows continued funding activity across European MedTech and adjacent HealthTech segments, providing context for MedVasc’s shareholder-backed raise.
Larger later-stage rounds include ProVerum (Ireland), which secured €68.6 million to advance a minimally invasive urology treatment, and SamanTree Medical (Belgium), which received €20 million from the European Investment Bank to support real-time surgical imaging technology.
Mid-range rounds include ShanX Medtech (Netherlands), which raised a combined €24 million to address antimicrobial resistance, and PIUR IMAGING (Austria), which secured €5.6 million to scale its 3D ultrasound imaging platform.
At the earlier stage, Ahead Health (Switzerland) raised €5.1 million for preventive healthcare services, and Doctor.One (Poland) raised €4 million to expand its chronic care model.
Together, these rounds represent approximately €130 million in disclosed funding flowing through European MedTech and HealthTech during this period. Against this backdrop, MedVasc’s financing is modest in size but consistent with early-stage European medical device companies focused on completing production, validation, and regulatory milestones ahead of commercial expansion.
MedVasc AB was founded in 2013 by Michael Åkesson; a senior consultant of interventional radiology with experience of over twenty years with catheter based treatments and diagnosis. Previously he was the Head of the Division of Endovascular Surgery at the Vascular Department, University Hospital SUS Malmö. He now works as a senior consultant at the Scandinavian Venous Centre, Malmö.
He is the main owner of MedVASC AB and the inventor behind Solutio.
MedVasc is also participating in SmiLe’s incubator programme – also based in Lund. SmiLe is a venture hub that specialises in advancing life science and FoodTech startups from concept to commercialisation. To date, their flagship incubator programme has supported over 110 startups, facilitating their collective acquisition of more than €1.05 billion in venture capital and contributing to 21 successful IPOs.
The company has developed and patented the medical device Solutio, designed to improve the anaesthetic procedure when treating varicose veins.
Solutio is designed to enable safe and precise local anesthesia during minimally invasive vascular procedures, e.g. varicose veins, (compatible with thermal ablation treatment fibers), offering a new level of control and patient comfort for clinicians treating chronic venous disorders.
It was developed to provide painless and precise local anesthesia during thermal treatment of venous insufficiency. The anesthesia catheter is compatible with so-called gold standard treatment fibers (RF/Laser) worldwide.
With the financing secured, MedVasc is well positioned to accelerate the remaining key activities required for FDA clearance of Solutio for the U.S. market. Preparations are progressing according to plan, and market approval is expected during autumn 2026.
Read the orginal article: https://www.eu-startups.com/2026/01/swedens-medvasc-raises-e2-2-million-for-anesthesia-catheter-as-it-moves-toward-us-approval/
